• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Coronavirus Publications
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Coronavirus Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Coleman, C.M.
    Venkataraman, T.
    Frieman, M.B.
    Date
    2014
    Journal
    Antimicrobial Agents and Chemotherapy
    Publisher
    American Society for Microbiology
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1128/AAC.03036-14
    Abstract
    Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.
    Keyword
    MERS-CoV
    SARS-CoV
    drug repurposing
    Middle East Respiratory Syndrome Coronavirus
    SARS Virus
    Coronavirus Infections--therapy
    Antiviral Agents
    Drug Repositioning
    Identifier to cite or link to this item
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902176510&doi=10.1128%2fAAC.03036-14&partnerID=40&md5=c82f3f5e8c97b8be79573df306c340a6; http://hdl.handle.net/10713/12417
    ae974a485f413a2113503eed53cd6c53
    10.1128/AAC.03036-14
    Scopus Count
    Collections
    UMB Coronavirus Publications

    entitlement

    Related articles

    • Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.
    • Authors: de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ
    • Issue date: 2014 Aug
    • Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.
    • Authors: LaFemina RL
    • Issue date: 2014 Aug
    • Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    • Authors: Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB
    • Issue date: 2016 Oct 1
    • 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    • Authors: Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S, Groutas WC, Chang KO
    • Issue date: 2020 Aug 19
    • Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i>.
    • Authors: Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, Reyes HM, Weiss SR, Frieman MB
    • Issue date: 2020 Oct 14
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.